Your browser doesn't support javascript.
Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction.
Malik, Jonaid Ahmad; Agrewala, Javed N.
  • Malik JA; Immunology laboratory, Indian Institute of Technology Ropar, Rupnagar, Punjab, India.
  • Agrewala JN; Immunology laboratory, Indian Institute of Technology Ropar, Rupnagar, Punjab, India. Electronic address: Jagrewala@iitrpr.ac.in.
Int Immunopharmacol ; 119: 110210, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-2299449
ABSTRACT
Substance Use Disorder (SUD) is one of the major mental illnesses that is terrifically intensifying worldwide. It is becoming overwhelming due to limited options for treatment. The complexity of addiction disorders is the main impediment to understanding the pathophysiology of the illness. Hence, unveiling the complexity of the brain through basic research, identification of novel signaling pathways, the discovery of new drug targets, and advancement in cutting-edge technologies will help control this disorder. Additionally, there is a great hope of controlling the SUDs through immunotherapeutic measures like therapeutic antibodies and vaccines. Vaccines have played a cardinal role in eliminating many diseases like polio, measles, and smallpox. Further, vaccines have controlled many diseases like cholera, dengue, diphtheria, Haemophilus influenza type b (Hib), human papillomavirus, influenza, Japanese encephalitis, etc. Recently, COVID-19 was controlled in many countries by vaccination. Currently, continuous effort is done to develop vaccines against nicotine, cocaine, morphine, methamphetamine, and heroin. Antibody therapy against SUDs is another important area where serious attention is required. Antibodies have contributed substantially against many serious diseases like diphtheria, rabies, Crohn's disease, asthma, rheumatoid arthritis, and bladder cancer. Antibody therapy is gaining immense momentum due to its success rate in cancer treatment. Furthermore, enormous advancement has been made in antibody therapy due to the generation of high-efficiency humanized antibodies with a long half-life. The advantage of antibody therapy is its instant outcome. This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Vacunas / Trastornos Relacionados con Sustancias / Difteria / Gripe Humana / COVID-19 Tipo de estudio: Estudio experimental / Estudio pronóstico Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: Int Immunopharmacol Asunto de la revista: Alergia e Inmunología / Farmacología Año: 2023 Tipo del documento: Artículo País de afiliación: J.intimp.2023.110210

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Vacunas / Trastornos Relacionados con Sustancias / Difteria / Gripe Humana / COVID-19 Tipo de estudio: Estudio experimental / Estudio pronóstico Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: Int Immunopharmacol Asunto de la revista: Alergia e Inmunología / Farmacología Año: 2023 Tipo del documento: Artículo País de afiliación: J.intimp.2023.110210